Abstract
Background: Higher monocyte count has been associated with disease progression and mortality in subjects with IPF.
Aim: To investigate the association between monocyte count and outcomes in subjects with progressive fibrosing ILDs other than IPF in the INBUILD trial.
Methods: We assessed associations between monocyte count ≤Q3 vs >Q3 at baseline and time to i) death, ii) acute ILD exacerbation or death, and iii) ILD progression (absolute decline in FVC ≥10% predicted) or death.
Results: In total, 332 subjects received nintedanib and 331 received placebo. At baseline, median monocyte count was 0.46 K/μL; Q3 was 0.60 K/μL. Mean (SD) FVC at baseline was 69.5 (15.1) and 67.4 (17.2) % predicted in subjects with monocyte count ≤Q3 and >Q3, respectively. Median exposure to trial drug was 17.4 months. In the placebo group, the risks of death and of acute ILD exacerbation or death were significantly greater in subjects with monocyte count >Q3 vs ≤Q3 at baseline, while the risk of ILD progression or death was only slightly increased. In the nintedanib group, there were numerical but not significant differences in the risk of these outcomes in subjects with monocyte count ≤Q3 vs >Q3 at baseline (Figure).
Conclusions: Data from the INBUILD trial suggest that high monocyte count may be associated with worse outcomes in subjects with progressive fibrosing ILDs other than IPF.
Footnotes
Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, OA2974.
This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2021
